| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥112.6B | ¥66.4B | +69.4% |
| Operating Income / Operating Profit | ¥32.4B | ¥-21.9B | +247.9% |
| Profit Before Tax | ¥30.4B | ¥-21.6B | +241.1% |
| Net Income / Net Profit | ¥17.9B | ¥-7.6B | +335.9% |
| ROE | 2.8% | -1.2% | - |
For FY2026 Q1, Revenue was ¥112.6B (¥66.4B in the prior-year period, +¥46.1B, +69.4%), Operating Income was ¥32.4B (¥-21.9B in the prior-year period, +¥54.4B, +247.9%), Ordinary Income was ¥31.8B (¥-21.2B in the prior-year period, +¥53.0B), and Net Income was ¥17.9B (¥-7.6B in the prior-year period, +¥25.5B, +335.9%), achieving a material revenue increase and turnaround to profitability. Gross profit margin improved to 90.1% (up +14.4pt from 75.7% in the prior-year period), reflecting a qualitative shift in the revenue mix toward higher-value products and license-type revenue. SG&A was ¥35.7B (¥37.0B in the prior-year period) and was absorbed by top-line growth, driving Operating Margin to 28.8% (improvement of +61.8pt from -33.0% in the prior-year period). Net margin was 15.9% (improvement of +27.3pt from -11.4% in the prior-year period), indicating notable single-quarter improvement in profitability. Conversely, Operating Cash Flow (OCF) was ¥-16.5B (turning negative from ¥6.1B in the prior-year period); an increase in accounts receivable and a decrease in accounts payable worsened working capital, preventing profit growth from converting into cash — a key issue.
[Revenue] Revenue of ¥112.6B represents high growth of +69.4% YoY. Cost of sales was ¥11.2B (¥16.2B in the prior-year period), producing a cost of sales ratio of 9.9% and gross profit of ¥101.4B (gross margin 90.1%). Gross margin improved by +14.4pt from 75.7% in the prior-year period, likely driven by a higher proportion of high-value products and growth in license/royalty-type revenue. As the company operates a single Pharmaceuticals segment, segmental breakdowns are not disclosed, but the significant top-line expansion suggests a qualitative transformation of the product portfolio.
[Profitability] SG&A of ¥35.7B was slightly down from ¥37.0B in the prior-year period; due to revenue growth SG&A ratio significantly improved to 31.7% (55.7% in the prior-year period). R&D expense was ¥30.3B (26.9% of revenue), reflecting continued aggressive pipeline investment. Operating Income of ¥32.4B turned positive from ¥-21.9B in the prior-year period, achieving an operating margin of 28.8%. Financial income was ¥1.4B versus financial expenses of ¥2.9B, net -¥1.4B. Other income was ¥4.2B versus other expenses of ¥7.2B (including impairment losses of ¥2.8B), net -¥3.0B. Equity-method losses were -¥0.6B, resulting in Profit Before Tax of ¥30.4B. After corporate taxes of ¥12.5B (effective tax rate 41.1%), Net Income was ¥17.9B (net margin 15.9%). The impairment loss of ¥2.8B recorded as an extraordinary item is temporary, but the high effective tax rate partially constrained net income growth. In conclusion, high gross margin structure and SG&A control contributed to a strong revenue-and-profit increase.
[Profitability] Operating Margin 28.8%, Net Margin 15.9%, Gross Margin 90.1% indicate a high-profitability profile. ROE 2.8% is decomposed as Net Margin 15.9% × Total Asset Turnover 0.084 × Financial Leverage 2.09x; while profitability is high, low total asset turnover suppresses overall efficiency. R&D-to-sales ratio 26.9% indicates an aggressive upfront investment phase typical for pharmaceuticals. [Cash Quality] With OCF of ¥-16.5B versus Net Income of ¥17.9B, OCF/Net Income is -0.92x, indicating profits are not converting into cash. OCF subtotal (before working capital changes) was ¥-13.9B, showing limited core cash generation; accounts receivable increase of -¥38.9B and accounts payable decrease of -¥25.5B substantially worsened working capital. [Investment Efficiency] Total asset turnover is low at 0.084x. Intangible assets are ¥535.8B (40.2% of total assets) and Goodwill is ¥255.6B (19.2% of total assets), so intellectual property and acquisition-related assets dominate the asset base, making short-term improvements in asset efficiency difficult. Days sales outstanding (DSO) has increased relative to the prior fiscal year-end, and collection management is a concern. [Financial Soundness] Equity Ratio is 47.8%. Interest-bearing debt (long-term borrowings ¥196.6B + bonds ¥261.6B + lease liabilities ¥42.1B) totals ¥500.3B, against cash and deposits of ¥116.0B, giving net interest-bearing debt of ¥384.3B and Debt/Equity ratio of 0.79x — within acceptable range. Financial expenses of ¥2.9B vs EBIT of ¥32.4B imply interest coverage of approximately 11.3x, so interest burden is modest. Current ratio 261% indicates ample short-term liquidity, though working capital deterioration constrains cash management.
OCF worsened to ¥-16.5B from ¥6.1B in the prior-year period. Starting from Profit Before Tax of ¥30.4B, depreciation and amortization of ¥11.0B, stock-based compensation expense of ¥4.5B, and impairment losses of ¥2.8B were added back, but an increase in trade receivables of -¥38.9B (accounts receivable increase with sales expansion) and a decrease in trade payables of -¥25.5B (presumed change in payment terms) worsened working capital by -¥62.1B, resulting in an OCF subtotal of ¥-13.9B. Inventories provided cash inflow of ¥1.3B, so inventory levels are broadly stable. Corporate tax payments were -¥2.0B, interest received ¥1.1B, interest paid -¥1.7B, and lease payments -¥2.1B, arriving at final OCF of ¥-16.5B. Investing Cash Flow was ¥-54.6B, primarily due to intangible asset acquisitions of -¥50.2B (presumed product rights and pipeline-related investments); capital expenditures of -¥3.0B were minor. Proceeds from sale of marketable securities were ¥11.5B and acquisition payments were -¥12.8B, net -¥1.4B. Free Cash Flow was ¥-71.2B. Financing Cash Flow was ¥-16.7B, mainly repayments of long-term borrowings -¥14.5B and lease liability repayments -¥2.2B. Adding foreign exchange translation effects of +¥0.2B, cash and cash equivalents decreased from ¥203.7B at the beginning of the period to ¥116.0B at period-end, a decline of -¥87.7B. Expanded working capital demand in a high-growth phase and large intangible investments are pressuring cash; improvement in receivables collection and normalization of payables will be key to improving liquidity.
Comprehensive income was ¥22.4B versus Net Income of ¥17.9B; Other Comprehensive Income (OCI) of ¥4.5B exceeded Net Income. OCI composition: non-recyclable items included valuation gains on fair-value-measured financial assets of ¥5.1B; recyclable items included foreign currency translation differences on foreign operations of -¥0.6B. The core recurring earnings driver is Gross Profit of ¥101.4B; Financial Income of ¥1.4B and Other Income of ¥4.2B are secondary. An impairment loss of ¥2.8B was recorded as a one-off expense and is included in Other Expenses of ¥7.2B. Operating Income of ¥32.4B reflects recurring achievements driven by high gross margins and SG&A control, but the divergence between OCF of ¥-16.5B and Net Income of ¥17.9B (OCF/Net Income -0.92x) raises concerns about accrual quality. The accounts receivable increase of -¥38.9B implies collection delay risk, and the accounts payable decrease of -¥25.5B could reflect temporary cash outflows due to changes in payment terms. As the main contributor to comprehensive income is fair value gains, which lack cash backing, attention is required; sustainability of earnings and improvement in cash conversion will be key evaluation criteria going forward.
Working capital management risk: Accounts receivable increased from ¥75.7B in the prior-year period to ¥115.9B (+50.1%), and DSO is trending longer. Accounts payable decreased from ¥74.9B to ¥49.0B (-34.6%), and working capital deteriorated by -¥62.1B, resulting in OCF turning negative to ¥-16.5B. It is necessary to determine whether this is a temporary phenomenon in an early high-growth phase or a structural deterioration in collection terms; continued DSO deterioration raises the risk of cash-flow failure.
Impairment risk on intangible assets: Intangible assets ¥535.8B (40.2% of total assets) and Goodwill ¥255.6B (19.2% of total assets) mean intellectual property and acquisition-related assets constitute ~60% of assets; if future cash-flow forecasts deteriorate, there is a risk of substantial impairment charges. The company recorded an impairment loss of ¥2.8B this period; significant impairment due to pipeline delays or market changes could erode equity and sharply reduce profitability.
Risk of sustained high effective tax rate: Profit Before Tax ¥30.4B vs corporate taxes ¥12.5B implies an effective tax rate of 41.1%, a high level. Deferred tax assets of ¥40.1B are recognized, but changes in projected taxable income or tax reforms could increase tax burden, making maintenance of a 15.9% net margin difficult and hindering ROE improvement. Regional tax structures and transparency of tax planning are limited, making quantitative assessment of tax risk challenging.
Profitability / Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 28.8% | – | – |
| Net Margin | 15.9% | – | – |
Operating Margin 28.8% and Net Margin 15.9% have materially improved YoY and indicate a clear shift to a high gross-margin structure; however, due to lack of industry median data, relative positioning is difficult to assess.
Growth / Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 69.4% | – | – |
Revenue growth of 69.4% is extremely high within the pharmaceutical industry and is presumed to reflect new product launches or rapid expansion of license revenue, but industry-comparison data are limited.
※ Source: Company compilation
Verification of the shift to a high gross-margin structure and its sustainability: Gross margin 90.1% (up +14.4pt from 75.7%) suggests a qualitative change in product mix, but license/royalty-type one-off revenue may be included. Monitoring gross margin trends and SG&A ratio from the next quarter onward will be important to assess sustainability of the high-profitability profile. Maintaining Operating Margin of 28.8% will require stabilization of the sales mix and continued cost control; expanded disclosure by product and by region is desirable.
Need to improve cash conversion: OCF ¥-16.5B, OCF/Net Income -0.92x, Free Cash Flow ¥-71.2B show that profit growth is not converting to cash. Working capital deterioration driven by accounts receivable increase of -¥38.9B and accounts payable decrease of -¥25.5B is the main cause; shortening receivable collection terms and normalizing payment terms are urgent. Intangible asset acquisitions of -¥50.2B can be viewed as growth investment, but the pace of monetization from these assets (royalties, milestone income) and improvement in OCF will be the mid-term inflection points for enterprise value. Cash and deposits of ¥116.0B and current ratio 261% ensure short-term payment ability, but sustainable growth is difficult without working capital normalization; DSO improvement and CCC shortening in the next quarter are key watch points.
This report is an earnings analysis document automatically generated by AI from XBRL financial statement data. It is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by our firm based on public financial statements. Investment decisions are your responsibility; please consult a professional advisor as necessary.